Latest Content

How drug pricing, tariffs, and manufacturing decisions are becoming connected.

President Trump has reportedly selected White House Domestic Policy Council deputy director Heidi Overton as his nominee for FDA commissioner.

Most pharma companies have promising AI pilots. Few have built the conditions to scale them. Here's what separates the leaders from the rest.

Rohit Tripathi, VP of Industry Strategy at RELEX, lays out the five signals that he believes can measure if the tariff policy is producing structural change.

LEO Pharma, BioMarin, OmniAb, and Chugai post a busy week of pharma dealmaking, RELEX's Rohit Tripathi weighs in on who ultimately pays for tariff-driven input costs, and Spherix Global Insights' Sybil Mead unpacks IRA-driven formulary pressure spreading across payer portfolios.

LEO Pharma agrees to acquire dersimelagon, OmniAb signs a ion channel discovery collaboration with Eli Lilly, Chugai grants GSK an exclusive worldwide license to AID351, and BioMarin acquires Alesta Therapeutics to gain ALE1.

Rohit Tripathi, VP of Industry Strategy at RELEX, talks about who will actually pay for the phased tariff-driven cost increases.

Spherix's VP of market access discusses how the IRA's maximum fair price is reshaping payer strategy, formulary design, and patient out-of-pocket costs far beyond negotiated drugs.

Henlius and Sandoz ink a biosimilars collaboration, ADVI's Tyler Seville makes the case for 340B reform, and RELEX's Rohit Tripathi weighs in on what real pharma reshoring requires.

Rohit Tripathi, VP of Industry Strategy at RELEX, discusses how pharmaceutical reshoring demands end-to-end capability not just domestic final assembly.

ADVI’s associate director of market access policy strategy discusses how 340B grew to $100 billion, lost its safety-net purpose, and became a compliance nightmare when the IRA arrived.

From a $1.32 billion rare epilepsy acquisition to AI drug discovery partnerships, biotech IPOs, and a rare disease investment rebound — here's what moved the market this week.

Pharmaceutical Executive releases its 2026 Top 50 company rankings, FDA grants Bristol Myers Squibb's Zenbexus accelerated approval for multiple myeloma, and PwC's Glenn Hunzinger talks the shifting economics of pharma dealmaking.